Effects of CYP2C19 genotype on out- comes of clopidogrel treatment. N Engl J Med. 2010;363:1704 14. 291. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909 17. 292. O Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989 97. 293. AstraZeneca. Brilinta REMS Document. Available at: http://www.fda. gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformation- forPatientsandProviders/UCM264004.pdf. Accessed July 26, 2012. 294. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361: 1045 57. 295. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544 54. 296. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel add- ed to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066 78. 297. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopido- grel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331 7. 298. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238 51. 299. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or tran- sient ischemic attack. Circulation. 2012;125:2914 21. 300. Verheugt FWA. Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke. Circulation. 2012;125:2821 3. 301. Shimada YJ, Nakra NC, Fox JT, et al. 